In a randomized trial, half of patients who received TULSA maintained both pad-free continence and erections at 6 months compared with one-quarter who had RP. Magnetic resonance imaging (MRI)-guided ...

Mar 27, 2026, 7:45 AM ETProfound Medical Corp. (PROF), PRN:CA The TULSA Procedure, performed using the TULSA-PRO ® system, represents a major advancement in prostate care, and is used by physicians to ...

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its ...

Traditional surgical and radiological approaches – along with a growing number of emerging technologies – to prostate cancer have made it a controllable disease for many men. At the same time, the ...

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...